Common errors, pitfalls, and management of complications of prostate biopsy : The most common diagnostic and procedural challenges of transrectal fusion prostate biopsy in the initial diagnosis of clinically significant prostate cancer

Abstract

Transrectal (TR) prostate biopsy is the gold standard in diagnosis of prostate cancer (PC). It requires aprecise and safe technique for sample acquisition. Several approaches will be discussed to avoid overdiagnosis, false-negative results, and complications of the procedure. We analyzed national and European guidelines, systematic reviews, meta-analyses, as well as prospective and retrospective studies to describe current trends in indication and performance of biopsies. Incorporation of risk calculators and magnetic resonance imaging (MRI) into daily routine reduces biopsy rates and results in amore precise diagnosis of clinically significant prostate cancer (csPC). Combination of random- and MRI-fusion guided biopsy-but also extending the radius of sampling by 10 mm beyond the MRI lesion and atransperineal (TP) sampling approach- lead to ahigher tumor-detection rate. Bleeding is the most common complication after prostate biopsy and is usually self-limiting. Postbiopsy infection rates can be reduced through TP biopsy. TR MRI-fusion guided biopsy is awidely acknowledged tool in primary diagnostics of csPC. Higher detection rates and safety can be achieved through aTP sampling approach.